NASDAQ:ORTX - Orchard Therapeutics News Headlines

Sign in or create an account to add this stock to your watchlist.
$16.53 -0.40 (-2.36 %)
(As of 04/26/2019 10:38 AM ET)
Previous Close$16.93
Today's Range$16.43 - $16.99
52-Week Range$8.65 - $21.64
Volume11,052 shs
Average Volume96,732 shs
Market Capitalization$1.42 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Orchard Therapeutics (NASDAQ ORTX) News Headlines

Source:
DateHeadline
Mustang Bio Looks To Change Scope Of Treatment For Bubble Boy DiseaseMustang Bio Looks To Change Scope Of Treatment For Bubble Boy Disease
seekingalpha.com - April 25 at 10:58 AM
Orchard launches study of cryopreserved gene therapy for rare immunodeficiency disorderOrchard launches study of cryopreserved gene therapy for rare immunodeficiency disorder
seekingalpha.com - April 25 at 10:58 AM
Orchard Therapeutics Announces First Patient Dosed with Cryopreserved Formulation of OTL-103 Gene Therapy for the Treatment of Wiskott-Aldrich SyndromeOrchard Therapeutics Announces First Patient Dosed with Cryopreserved Formulation of OTL-103 Gene Therapy for the Treatment of Wiskott-Aldrich Syndrome
finance.yahoo.com - April 25 at 10:58 AM
Zacks: Analysts Expect Orchard Therapeutics PLC - (ORTX) Will Post Quarterly Sales of $560,000.00Zacks: Analysts Expect Orchard Therapeutics PLC - (ORTX) Will Post Quarterly Sales of $560,000.00
www.americanbankingnews.com - April 24 at 5:39 AM
Contrasting Orchard Therapeutics (ORTX) and Its PeersContrasting Orchard Therapeutics (ORTX) and Its Peers
www.americanbankingnews.com - April 23 at 10:12 PM
 Analysts Expect Orchard Therapeutics PLC - (ORTX) Will Announce Earnings of -$0.49 Per Share Analysts Expect Orchard Therapeutics PLC - (ORTX) Will Announce Earnings of -$0.49 Per Share
www.americanbankingnews.com - April 22 at 2:12 AM
Orchard Therapeutics PLC -s Lock-Up Period Set To End  on April 29th (NASDAQ:ORTX)Orchard Therapeutics PLC -'s Lock-Up Period Set To End on April 29th (NASDAQ:ORTX)
www.americanbankingnews.com - April 22 at 1:02 AM
Orchard Therapeutics PLC - (ORTX) Given Consensus Rating of "Buy" by AnalystsOrchard Therapeutics PLC - (ORTX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - April 21 at 6:52 AM
Comparing Orchard Therapeutics (ORTX) & The CompetitionComparing Orchard Therapeutics (ORTX) & The Competition
www.americanbankingnews.com - April 19 at 8:16 PM
Financial Comparison: Orchard Therapeutics (ORTX) & The CompetitionFinancial Comparison: Orchard Therapeutics (ORTX) & The Competition
www.americanbankingnews.com - April 19 at 6:18 PM
Data Supports Achievement of Proof-of-Concept Milestone for OTL-300Data Supports Achievement of Proof-of-Concept Milestone for OTL-300
www.globenewswire.com - April 15 at 8:43 AM
Orchard Therapeutics Announces Presentation of Clinical Proof-of-Concept for OTL-300 for the Treatment of Transfusion-Dependent Beta-Thalassemia at the 22nd American Society of Gene & Cell Therapy Annual MeetingOrchard Therapeutics Announces Presentation of Clinical Proof-of-Concept for OTL-300 for the Treatment of Transfusion-Dependent Beta-Thalassemia at the 22nd American Society of Gene & Cell Therapy Annual Meeting
finance.yahoo.com - April 15 at 8:43 AM
Orchard Therapeutics (ORTX) vs. The Competition Head-To-Head AnalysisOrchard Therapeutics (ORTX) vs. The Competition Head-To-Head Analysis
www.americanbankingnews.com - April 14 at 6:21 PM
Reviewing Orchard Therapeutics (ORTX) and Its PeersReviewing Orchard Therapeutics (ORTX) and Its Peers
www.americanbankingnews.com - April 8 at 10:18 AM
Orchard gene therapy shows positive effect MLD studyOrchard gene therapy shows positive effect MLD study
seekingalpha.com - March 27 at 3:40 PM
Orchard Therapeutics Presents New Registrational Data Demonstrating Sustained Clinical Benefit of OTL-200 for the Treatment of MLDOrchard Therapeutics Presents New Registrational Data Demonstrating Sustained Clinical Benefit of OTL-200 for the Treatment of MLD
finance.yahoo.com - March 27 at 9:48 AM
Will Orchard Therapeutics Continue to Surge Higher?Will Orchard Therapeutics Continue to Surge Higher?
finance.yahoo.com - March 27 at 9:48 AM
Orchard Therapeutics Reports 2018 Financial Results and Reviews Recent Business HighlightsOrchard Therapeutics Reports 2018 Financial Results and Reviews Recent Business Highlights
finance.yahoo.com - March 21 at 11:28 AM
Orchard Therapeutics plc (ORTX)Orchard Therapeutics plc (ORTX)
finance.yahoo.com - March 20 at 8:32 PM
Orchard Therapeutics plcOrchard Therapeutics plc
www.bloomberg.com - March 18 at 3:38 PM
What Kind Of Shareholders Own Orchard Therapeutics plc (NASDAQ:ORTX)?What Kind Of Shareholders Own Orchard Therapeutics plc (NASDAQ:ORTX)?
finance.yahoo.com - March 16 at 9:23 AM
Orchard Therapeutics to Webcast Conference Call of 2018 Financial Results on March 21, 2019Orchard Therapeutics to Webcast Conference Call of 2018 Financial Results on March 21, 2019
finance.yahoo.com - March 14 at 9:31 AM
Orchard Therapeutics Announces Acceptance of OTL-200 Abstract for MLD at the 45th Annual Meeting of the European Society for Blood and Bone Marrow Transplantation (EBMT)Orchard Therapeutics Announces Acceptance of OTL-200 Abstract for MLD at the 45th Annual Meeting of the European Society for Blood and Bone Marrow Transplantation (EBMT)
finance.yahoo.com - March 11 at 8:30 AM
Orchard Therapeutics up 12% on positive OTL-102 dataOrchard Therapeutics up 12% on positive OTL-102 data
seekingalpha.com - February 25 at 11:50 AM
Orchard Therapeutics Presents Clinical Proof-of-Concept Data for OTL-102 for the Treatment of X-CGDOrchard Therapeutics Presents Clinical Proof-of-Concept Data for OTL-102 for the Treatment of X-CGD
finance.yahoo.com - February 25 at 11:50 AM
Orchard gene therapy shows positive action in rare inherited immune deficiency disorderOrchard gene therapy shows positive action in rare inherited immune deficiency disorder
seekingalpha.com - February 22 at 3:30 PM
Orchard Therapeutics Presents Two-Year Follow-Up Data Versus Historical Control from Registrational Trial of OTL-101 for the Treatment of ADA-SCIDOrchard Therapeutics Presents Two-Year Follow-Up Data Versus Historical Control from Registrational Trial of OTL-101 for the Treatment of ADA-SCID
finance.yahoo.com - February 22 at 3:30 PM
Orchard Therapeutics Announces Acceptance of Late-Breaking Abstracts of OTL-101 for ADA-SCID and OTL-102 for X-CGD at the 2019 Transplantation and Cellular Therapy Meetings of ASBMT and CIBMTROrchard Therapeutics Announces Acceptance of Late-Breaking Abstracts of OTL-101 for ADA-SCID and OTL-102 for X-CGD at the 2019 Transplantation and Cellular Therapy Meetings of ASBMT and CIBMTR
finance.yahoo.com - February 6 at 8:29 AM
Publication Highlights Encouraging Evidence of OTL-300’s Safety and Efficacy in Transfusion-Dependent Beta-Thalassemia PatientsPublication Highlights Encouraging Evidence of OTL-300’s Safety and Efficacy in Transfusion-Dependent Beta-Thalassemia Patients
globenewswire.com - January 22 at 7:43 AM
Orchard Announces Publication by San Raffaele-Telethon Institute for Gene Therapy of OTL-300 Clinical Data for the Treatment of Transfusion-Dependent Beta-Thalassemia in Nature MedicineOrchard Announces Publication by San Raffaele-Telethon Institute for Gene Therapy of OTL-300 Clinical Data for the Treatment of Transfusion-Dependent Beta-Thalassemia in Nature Medicine
finance.yahoo.com - January 22 at 7:43 AM
Orchard Therapeutics provides 2019 strategic prioritiesOrchard Therapeutics provides 2019 strategic priorities
seekingalpha.com - January 7 at 3:22 PM
Orchard Therapeutics Highlights Recent Accomplishments and 2019 Strategic Priorities as a Global Leader in Gene TherapyOrchard Therapeutics Highlights Recent Accomplishments and 2019 Strategic Priorities as a Global Leader in Gene Therapy
finance.yahoo.com - January 7 at 3:22 PM
Orchard Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019Orchard Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019
finance.yahoo.com - January 3 at 6:53 AM
2019 biotech preview: Money is pouring into the Bay Area and so is Big Pharma2019 biotech preview: Money is pouring into the Bay Area and so is Big Pharma
finance.yahoo.com - December 28 at 3:17 PM
Positive Data From Orchard Therapeutics Turns Goldman Sachs BullishPositive Data From Orchard Therapeutics Turns Goldman Sachs Bullish
www.benzinga.com - December 17 at 3:18 PM
Orchard Therapeutics and SIRION Biotech Announce Licensing Agreement to Enhance Gene Therapy Manufacturing EfficiencyOrchard Therapeutics and SIRION Biotech Announce Licensing Agreement to Enhance Gene Therapy Manufacturing Efficiency
globenewswire.com - December 14 at 3:18 PM
Orchard Therapeutics and SIRION Biotech inks deal to enhance gene therapy manufacturing efficiencyOrchard Therapeutics and SIRION Biotech inks deal to enhance gene therapy manufacturing efficiency
seekingalpha.com - December 14 at 3:18 PM
Orchard Therapeutics Announces the Build-out of New Gene Therapy Manufacturing Facility in CaliforniaOrchard Therapeutics Announces the Build-out of New Gene Therapy Manufacturing Facility in California
finance.yahoo.com - December 13 at 7:53 AM
Donald B. Kohn, MD, Orchard Therapeutics Scientific Advisory Board Member, Presents Clinical Proof-of-Concept Data for OTL-102 Gene Therapy for the Treatment of Patients with X-CGD at the Presidential Symposium at the 2018 ASH Annual MeetingDonald B. Kohn, MD, Orchard Therapeutics Scientific Advisory Board Member, Presents Clinical Proof-of-Concept Data for OTL-102 Gene Therapy for the Treatment of Patients with X-CGD at the Presidential Symposium at the 2018 ASH Annual Meeting
finance.yahoo.com - December 5 at 3:16 PM
Orchard Therapeutics PLC ADROrchard Therapeutics PLC ADR
www.barrons.com - November 30 at 3:15 PM
Orchard Therapeutics Announces Closing of $225 Million Initial Public Offering, Including the Partial Exercise of Underwriters’ OptionOrchard Therapeutics Announces Closing of $225 Million Initial Public Offering, Including the Partial Exercise of Underwriters’ Option
finance.yahoo.com - November 28 at 8:40 AM
Orchard Therapeutics Strengthens Global Commercial Leadership Team with Appointments of Heads of US and EMEA Region Commercial OperationsOrchard Therapeutics Strengthens Global Commercial Leadership Team with Appointments of Heads of US and EMEA Region Commercial Operations
finance.yahoo.com - November 28 at 8:40 AM
This page was last updated on 4/26/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel